期刊
BRAIN STIMULATION
卷 11, 期 2, 页码 337-345出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.brs.2017.11.004
关键词
repetitive transcranial magnetic stimulation (rTMS); Cognitive-behavioral therapy (CBT); Major depressive disorder (MDD); Treatment outcome; Clinical predictors
资金
- American Psychiatric Association
- Brain Resource Ltd.
- Compass Inc.
- Curbstone Consultant LLC
- Eli Lilly
- Emmes Corp.
- Liva-Nova
- Lundbeck A/S
- National Institute of Drug Abuse
- Taj Medical
- Santium Inc.
- Sunovion
- Takeda USA
- Live Nova
Background: Repetitive transcranial magnetic stimulation (rTMS) is considered an efficacious non-invasive neuromodulation treatment for major depressive disorder (MDD). However, little is known about the clinical outcome of combined rTMS and psychotherapy (rTMS thorn PT). Through common neurobiological brain mechanisms, rTMS thorn PT may exert enhanced antidepressant effects compared to the respective monotherapies. Objective: The current naturalistic study aimed to evaluate feasibility and clinical outcome of rTMS thorn PT in a large group of MDD patients. The second aim was to identify clinical predictors of response and remission. Methods: A total of 196 patients with MDD were treated with at least 10 sessions of simultaneous rTMS and PT. rTMS was applied over the DLPFC, either 10 Hz left or 1 Hz right. Psychotherapy was based on principles of cognitive behavioral therapy (CBT). Symptoms were measured using the BDI each fifth session until end of treatment and at 6-month follow-up. Comparisons were made between responders and non-responders, as well as between the 10 Hz and 1 Hz protocol. Additionally, baseline variables and early BDI change were evaluated as predictors of response/remission. Major findings and conclusions: 1) Combining rTMS and PT resulted in a 66% response and a 56% remission rate at the end of treatment with 60% sustained remission at follow-up. Compared to previous findings in RCTs, these rates are relatively high; 2) No differences were found between the 10 Hz and 1 Hz TMS regarding clinical outcome; 3) Clinical baseline variables were not predictive of treatment outcomes; 4) Early symptom improvement (at session 10) was highly predictive of response, and may therefore be used to guide rTMS thorn PT continuation; 5) Based on the current findings in a large naturalistic study, future studies employing a more standardized method are warranted to draw solid conclusions on the unique effect of rTMS thorn PT. (C) 2017 The Author(s). Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据